Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAlogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
Journal of the American Geriatrics Society, 10/13/09
Pratley RE et al. – Alogliptin was effective and well tolerated in the elderly patients enrolled in these studies. Improvements in HbA1c were similar to those seen in younger patients, and no increase in the risk of hypoglycemia, weight gain, or other adverse events was apparent in elderly patients.
Related Articles
Diabetes and obesity in older adults: a call to action
Reviews in Clinical Gerontology, 11/11/09
Relevance Score: 79%
Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents
Diabetic Medicine, 11/10/09
Relevance Score: 79%
Generational status and duration of residence predict diabetes prevalence among Latinos: the California Men's Health Study
BMC Public Health, 10/27/09
Relevance Score: 79%
Age-Associated Increase in Abdominal Obesity and Insulin Resistance, and Usefulness of AHA/NHLBI Definition of Metabolic Syndrome for Predicting Cardiovascular Disease in Japanese Elderly with Type 2 Diabetes Mellitus
Gerontology, 10/19/09
Relevance Score: 79%
Heterogeneity of body mass index, waist circumference, and waist-to-hip ratio in predicting obesity-related metabolic disorders for Taiwanese aged 35-64y
Clinical Nutrition, 10/15/09
Relevance Score: 79%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Inflammatory breast cancer: what are the treatment options
Expert Opinion in Pharmacotherapy, 12/08/09
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Expert Opinion on Investigational Drugs, 12/08/09
Sponsor
Article Search
Sponsor